InvestSMART

Pharmaxis Ltd (ASX: PXS) - Announcements

- Current share price for PXS : $0.027

ASX company news and announcements for Pharmaxis Ltd (PXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pharmaxis Ltd (PXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pharmaxis Ltd (PXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pharmaxis Ltd (PXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Pharmaxis Receives Maximum Extension to German Patent 27 Sep 2012 8:51AM $1.100 $0.027 fallen by 97.55%
- Preliminary Final Report 10 Aug 2012 8:35AM $1.125 $0.027 fallen by 97.60%
- US FDA Accepts Bronchitol New Drug Application for Review 2 Aug 2012 1:00PM $1.180 $0.027 fallen by 97.71%
- Appendix 4C - quarterly 17 Jul 2012 4:15PM $1.095 $0.027 fallen by 97.53%
- Additional Data Bronchitol Reduces Risk of Exacerbations 8 Jun 2012 8:41AM $1.090 $0.027 fallen by 97.52%
- Bronchitol Commercial Progress in Europe 1 Jun 2012 9:33AM $1.060 $0.027 fallen by 97.45%
- Pharmaxis Submits US New Drug Application for Bronchitol 21 May 2012 9:31AM $1.080 $0.027 fallen by 97.50%
- Pharmaxis Receives Approval to Market Bronchitol in the EU 20 Apr 2012 9:36AM $1.300 $0.027 fallen by 97.92%
- Appendix 4C - quarterly 18 Apr 2012 4:23PM n/a $0.027 n/a
- PXS Completes Phase II study with ASM8 in asthma patients 17 Apr 2012 8:34AM $1.255 $0.027 fallen by 97.85%
- Pharmaxis Announces Agreement for EU Supply of Bronchitol 29 Mar 2012 9:18AM $1.360 $0.027 fallen by 98.01%
- European Regulatiry Update on Bronchitol 16 Mar 2012 9:00AM $1.230 $0.027 fallen by 97.80%
- Bronchitol to be Reimbursed in Australia 14 Mar 2012 12:46PM $1.180 $0.027 fallen by 97.71%
- Half Yearly Report and Accounts 3 Feb 2012 8:23AM $1.005 $0.027 fallen by 97.31%
- Appendix 4C - quarterly 24 Jan 2012 4:54PM $0.990 $0.027 fallen by 97.27%
- Pharmaxis Files PBAC Minor Resubmission for Bronchitol 20 Dec 2011 9:27AM $1.045 $0.027 fallen by 97.42%
- Phase 3 Trial in Bronchiectasis Reaches Recruitment Target 13 Dec 2011 10:25AM $1.055 $0.027 fallen by 97.44%
- Retail Offer Booklet 24 Nov 2011 8:36AM $1.025 $0.027 fallen by 97.37%
- Institutional Component of Entitlement Offer 18 Nov 2011 9:59AM $1.115 $0.027 fallen by 97.58%
- Trading Halt 16 Nov 2011 10:00AM $1.300 $0.027 fallen by 97.92%
- Pharmaxis Announces PBAC Decision on Bronchitol 9 Nov 2011 4:15PM $1.360 $0.027 fallen by 98.01%
- Pharmaxis Announces Positive Bronchitol Opinion for Europe 24 Oct 2011 8:38AM $1.410 $0.027 fallen by 98.09%
- Reinstatement to Official Quotation 24 Oct 2011 8:38AM $1.410 $0.027 fallen by 98.09%
- Suspension from Official Quotation 20 Oct 2011 8:31AM $0.940 $0.027 fallen by 97.13%
- Trading Halt 17 Oct 2011 5:17PM $0.940 $0.027 fallen by 97.13%

651 - 675 of 836 results

Page 27 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.